Rivastigmine Patch, Extended Release
Product Images NDC 16714-116

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 16714-116). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 01

Chemical structure of Rivastigmine, depicting its molecular bonds and arrangement, including aromatic ring and various functional groups, as submitted by Northstar Rx LLC.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 02

An illustration showing a cross-sectional diagram with four distinct layers labeled Layer 1, Layer 2, Layer 3, and Layer 4. Each layer is visually differentiated by unique shading or pattern styles, arranged vertically from top to bottom.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 03

A line graph showing Rivastigmine concentration (ng/mL) over 24 hours for three dosage strengths: 13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours. The x-axis represents time in hours, and the y-axis represents Rivastigmine levels. Data points for each dosage are indicated with different symbols, showing the concentration profiles with error bars for variability.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 04

Line graph depicting clinical changes over 24 weeks of treatment on the ADAS-Cog rating from baseline. It compares least square means (+/- SEM) change among four groups: Rivastigmine 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo. The y-axis measures clinical improvement versus decline, and the x-axis measures weeks during treatment.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 05

A bar chart depicting the percentage of patients categorized by ADCS-CGIC rating across four treatment groups: 17.4 mg/24 hours, 9.5 mg/24 hours, Capsules 6 mg BID, and Placebo. Ratings include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse, with No Change having the highest patient percentages in all groups.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 06

Line graph comparing the mean change from baseline in ADCS-ADL scores over 48 weeks for Rivastigmine Transdermal System 13.3 mg/24 hr and 9.5 mg/24 hr doses. The graph shows clinical improvement and decline trends during treatment, with statistical significance indicated between the two doses.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 07

A line graph comparing ADAS-Cog change from baseline in patients treated with Rivastigmine Transdermal System 13.3 mg/24 hr and 9.5 mg/24 hr over 48 weeks. The y-axis represents change in cognition (lower scores indicate improvement), and the x-axis shows weeks of treatment. The 13.3 mg/24 hr dose shows less clinical decline than the 9.5 mg/24 hr dose at later time points.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 08

A line graph comparing the efficacy of Rivastigmine Transdermal System 13.3 mg/24 hr and 4.6 mg/24 hr over 24 weeks of treatment. The graph shows least squares mean change with standard error bars, indicating clinical improvement or decline, with statistical significance noted for changes at 16 and 24 weeks but not at 8 weeks.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 09

A line chart comparing the least squares mean change plus or minus standard error of Rivastigmine Transdermal System at 13.3 mg/24 hr and 4.6 mg/24 hr over 24 weeks of treatment. The y-axis measures LS mean change indicating clinical improvement or decline. Data points at weeks 8, 16, and 24 show mean differences with 95% confidence intervals and p-values assessing statistical significance.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 10

Illustration of the Rivastigmine Transdermal System packaging and components by Northstar Rx LLC. The diagram shows the sealed pouch labeled with the product name, a circular patch with protective liners, and the patch's adhesive side and outside backing labeled. The patch delivers rivastigmine for transdermal use.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 11

Diagram showing possible application sites for a Rivastigmine patch on the body, including left or right upper arm, left or right side of chest, left or right upper back, and left or right lower back. Each site is depicted with front, side, or back views indicating placement areas with shaded rectangles.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 12

An illustration showing a hand holding a Rivastigmine Transdermal System packet with instructions to open it by cutting along the edge using scissors. The packet is labeled for transdermal use only and contains one system, with branding from Northstar.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 13

An instructional illustration showing two hands peeling apart a protective backing to reveal a round adhesive patch, demonstrating how to open a medication patch packaging, possibly for Rivastigmine transdermal patches.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 14

An instructional line drawing illustrating the removal of protective liners from the sticky surface of a transdermal system patch, likely representing the Rivastigmine transdermal patch. The diagram shows two hands peeling off the transparent liners from the circular adhesive patch.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 15

Illustration showing the application of a transdermal patch to a person's upper back. One hand holds the patch while the other hand presses it onto the skin, demonstrating proper placement and adhesion technique for a patch medication.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 16

An instructional illustration showing a person applying a patch onto the upper back area. The diagram depicts a hand placing the patch on the upper right side of the back between the shoulder blade and spine, indicating proper site placement for a transdermal medication patch.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 17

An instructional illustration showing a person applying a patch to the upper chest area. The image depicts one hand placing the patch while the other hand holds it, with an arrow indicating the motion of attaching or smoothing the patch onto the skin.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 18

Illustration showing disposal instructions for Rivastigmine transdermal system patches by Northstar Rx LLC. Three frames demonstrate folding sticky sides of the patch together, sliding the folded patch into the empty pouch it came in, and placing the pouch into a trash can while keeping it away from children and pets.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 19

Rivastigmine Transdermal System packaging label, each delivering 4.6 mg/24 hours. The label indicates the box contains 30 systems for transdermal use only. Manufactured for Northstar Rx LLC with manufacturer Cadila Healthcare Limited in India. The label includes instructions for discarding used patches and warnings to keep out of reach of children. NDC 16714-115-02 is printed on the packaging.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 20

Packaging label for Rivastigmine Transdermal System delivering 9.5 mg/24 hours, manufactured for Northstar Rx LLC. The label states it contains 30 systems and is for transdermal use only. It includes instructions for discarding the patch safely, storage conditions, and manufacturer info from Cadila Healthcare Limited, India. The NDC number 16714-116-02 is visible along with the NorthStar logo.*

FDA Label Image

6fc311c0 7c2b 4cdd 8304 8ee41da02a91 21

Rivastigmine Transdermal System 13.3 mg/24 hours packaging label from Northstar Rx LLC. The carton states it contains 30 transdermal systems, each delivering 13.3 mg of rivastigmine per 24 hours. The label includes usage instructions, storage conditions, and safety warnings, with manufacturing information for Northstar Rx LLC and Cadila Healthcare Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.